What is the standard initial therapy for an adult with newly diagnosed diffuse large B‑cell lymphoma?

Standard Initial Therapy for Diffuse Large B-Cell Lymphoma

R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) given every 21 days remains the standard initial therapy for most adults with newly diagnosed diffuse large B-cell lymphoma, with treatment stratified by age and risk profile. 1

Treatment Algorithm by Patient Population

Patients Aged 60-80 Years

• Eight cycles of R-CHOP-21 (given every 21 days) is the established standard of care 1
• R-CHOP-14 (every 14 days) showed no survival advantage over R-CHOP-21 and should not be used 1
• If R-CHOP-14 is used, six cycles of CHOP with eight cycles of rituximab are sufficient 1
• For localized disease in this age group, consolidation radiotherapy provides no benefit 1

Young Patients (<60 Years) - Risk-Stratified Approach

Low-intermediate risk (aaIPI = 1) or low risk (aaIPI = 0) with bulky disease:

• R-CHOP-21 × 6 cycles with radiotherapy to sites of previous bulky disease 1
• Alternative option: R-ACVBP (rituximab, doxorubicin, vindesine, cyclophosphamide, bleomycin, prednisolone every 2 weeks with sequential consolidation) has shown improved survival compared to eight cycles of R-CHOP, though radiotherapy was omitted in this trial 1

High and high-intermediate risk (aaIPI ≥ 2):

• No current standard exists for this subgroup; clinical trial enrollment is strongly preferred 1
• Most commonly applied: six to eight cycles of R-CHOP-21 1
• R-CHOP-14 has not demonstrated survival benefit in this population 1

Patients Aged >80 Years

• Comprehensive geriatric assessment should determine treatment intensity 1
• R-CHOP can be used until age 80 in healthy patients 1
• R-miniCHOP (attenuated chemotherapy with rituximab) can induce complete remission and long survival in healthy patients >80 years 1
• Consider doxorubicin substitution with etoposide or liposomal doxorubicin, or omission entirely, in patients with cardiac dysfunction 1

Emerging Standard for High-Risk Patients

For patients with International Prognostic Index (IPI) ≥ 2, polatuzumab vedotin-R-CHP has shown superior progression-free survival compared to R-CHOP and represents a new treatment option 2, 3. This antibody-drug conjugate combination is increasingly considered for higher-risk disease 4.

CNS Prophylaxis Considerations

• Patients with high-intermediate and high-risk IPI, especially those with >1 extranodal site or elevated LDH, require CNS prophylaxis 1
• Intrathecal methotrexate alone is probably not optimal 1
• Intravenous high-dose methotrexate with efficient disease control is a preferred alternative 1
• Testicular lymphoma mandates CNS prophylaxis 1

Critical Management Points

Tumor Lysis Syndrome Prevention

• In high tumor burden cases, administer prednisone 100 mg orally for several days as "prephase" treatment to prevent tumor lysis syndrome 1

Dose Intensity Maintenance

• Avoid dose reductions due to hematological toxicity 1
• Febrile neutropenia justifies prophylactic hematopoietic growth factors in all patients treated with curative intent and all elderly patients 1

Special Considerations for Specific Subtypes

Primary CNS DLBCL:

• Must contain high-dose methotrexate 1
• Addition of high-dose cytarabine improves complete remission rates and outcomes 1

Primary testicular DLBCL:

• R-CHOP-21 with CNS prophylaxis and contralateral testis irradiation for localized disease (stage I-II) 1

Primary mediastinal large B-cell lymphoma:

• R-CHOP-21 is not definitively established; radiotherapy remains controversial 1

Common Pitfalls to Avoid

• Do not use R-CHOP-14 expecting improved outcomes—it provides no survival advantage over R-CHOP-21 1
• Do not omit growth factor support in elderly patients or those with febrile neutropenia during curative treatment 1
• Do not reduce doses for hematological toxicity; maintain dose intensity for curative outcomes 1
• Do not rely solely on intrathecal methotrexate for CNS prophylaxis in high-risk patients 1